World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer
Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer
LUND, Sweden – The days between 10 to 15 of May, 2016 were dedicated to the deadliest form of cancer, pancreatic cancer, by two major events that took place in Orlando, USA: the first World Pancreatic Cancer Coalition (WPCC) followed by the third AACR Pancreatic Cancer Special Conference. Both events represented major breakthroughs for Immunovia and IMMray™ PanCan-d as the following main areas in pancreatic cancer were emphasized:
Firstly, the largest global patient advocacy pancreatic cancer coalition was formed to provide a united front against this lethal disease. Immunovia sponsors the patient advocacy world coalition and will work closely with the members on both national and global levels.
Secondly, the main focus of pancreatic cancer care is now clearly early detection of stages I & II for improved chances of patient survival. Prof Borrebaeck’s talk presented clinical studies results covering over 2500 pancreatic cancer blood samples that show that IMMray™ PanCan-d can detect stages I, II, III and IV patients with an accuracy of 98%. The Scandinavian study that was finalized last year, was presented for the first time at this event and the data (that were initially press released in Nov 2015: link) showed that Immunovia’s test is able to detect the early stages of pancreatic cancer in blood with unprecedented accuracy of 96%. The talk received fantastic response from the conference participants and particularly from Key Opinion Leaders.
Thirdly, the high risk group of late onset diabetes after 50 years of age was strongly brought forward as an area that needs immediate and increased priority. Immunovia has commenced discussions to participate in the late onset diabetes programs underway.
To read the complete summary from the WPCC and AACR Pancreatic Cancer Special Conference in Orlando, click here (PDF).
Laura Chirica, PhD, Immunovia, Sweden
Press release PDF